A 52-week multicenter, randomized, parallel-group trial in overweight people investigating lifestyle changes, mushroom supplementation and bupropion to reduce adiposity and cardiometabolic risk

Condition studied

Overweight or class I obesity (BMI 25.0–34.9 kg/m²), with or without cardiometabolic risk factors (hypertension, hyperlipidemia, and/or prediabetes).

Investigational medicinal product(s)

Every trial of Bupropion across our registers →

Eligibility

Primary endpoint

Percent change in body weight from baseline to 6 months, with absolute change in body weight (kg) as a supportive measure.

Endpoint detail

Proportion of participants achieving ≥5% reduction in body weight from baseline., Participants will be classified into ordered categories based on obesity status (BMI ≥30 kg/m² vs <30 kg/m²) and number of cardiometabolic risk conditions (central adiposity, hypertension, hyperlipidemia, prediabetes/type 2 diabetes), forming a composite ordinal outcome analyzed using proportional odds models.